{ "instance": { "f10q0323_jasperthera.htm": { "axisCustom": 0, "axisStandard": 12, "baseTaxonomies": { "http://fasb.org/srt/2023": 1, "http://fasb.org/us-gaap/2023": 468, "http://xbrl.sec.gov/dei/2023": 34 }, "contextCount": 79, "dts": { "calculationLink": { "local": [ "jspr-20230331_cal.xml" ] }, "definitionLink": { "local": [ "jspr-20230331_def.xml" ] }, "inline": { "local": [ "f10q0323_jasperthera.htm" ] }, "labelLink": { "local": [ "jspr-20230331_lab.xml" ] }, "presentationLink": { "local": [ "jspr-20230331_pre.xml" ] }, "schema": { "local": [ "jspr-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] } }, "elementCount": 471, "entityCount": 1, "hidden": { "http://Amplitudehealthcare.com/20230331": 12, "http://fasb.org/us-gaap/2023": 57, "http://xbrl.sec.gov/dei/2023": 5, "total": 74 }, "keyCustom": 79, "keyStandard": 249, "memberCustom": 9, "memberStandard": 14, "nsprefix": "jspr", "nsuri": "http://Amplitudehealthcare.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://Amplitudehealthcare.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "11", "role": "http://Amplitudehealthcare.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:CondensedFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Condensed Consolidated Balance Sheet Components", "menuCat": "Notes", "order": "12", "role": "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponents", "shortName": "Condensed Consolidated Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:CondensedFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "jspr:CirmGrantDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Cirm Grant", "menuCat": "Notes", "order": "13", "role": "http://Amplitudehealthcare.com/role/CirmGrant", "shortName": "Cirm Grant", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "jspr:CirmGrantDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "jspr:SignificantAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Significant Agreements", "menuCat": "Notes", "order": "14", "role": "http://Amplitudehealthcare.com/role/SignificantAgreements", "shortName": "Significant Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "jspr:SignificantAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Derivative Financial Instruments", "menuCat": "Notes", "order": "15", "role": "http://Amplitudehealthcare.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "16", "role": "http://Amplitudehealthcare.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "jspr:CommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Common Stock", "menuCat": "Notes", "order": "17", "role": "http://Amplitudehealthcare.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "jspr:CommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "18", "role": "http://Amplitudehealthcare.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Net Loss Per Share Attributable to Common Stockholders", "menuCat": "Notes", "order": "19", "role": "http://Amplitudehealthcare.com/role/NetLossPerShareAttributabletoCommonStockholders", "shortName": "Net Loss Per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c5", "decimals": "-3", "lang": null, "name": "us-gaap:OtherReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Related Parties", "menuCat": "Notes", "order": "20", "role": "http://Amplitudehealthcare.com/role/RelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "21", "role": "http://Amplitudehealthcare.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "22", "role": "http://Amplitudehealthcare.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "23", "role": "http://Amplitudehealthcare.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)", "menuCat": "Tables", "order": "24", "role": "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponentsTables", "shortName": "Condensed Consolidated Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "25", "role": "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Common Stock (Tables)", "menuCat": "Tables", "order": "26", "role": "http://Amplitudehealthcare.com/role/CommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "27", "role": "http://Amplitudehealthcare.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)", "menuCat": "Tables", "order": "28", "role": "http://Amplitudehealthcare.com/role/NetLossPerShareAttributabletoCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c6", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Organization and Description of Business (Details)", "menuCat": "Details", "order": "29", "role": "http://Amplitudehealthcare.com/role/OrganizationandDescriptionofBusinessDetails", "shortName": "Organization and Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c6", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of cash and cash equivalents and restricted cash", "menuCat": "Details", "order": "30", "role": "http://Amplitudehealthcare.com/role/ScheduleofreconciliationofcashandcashequivalentsandrestrictedcashTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of cash and cash equivalents and restricted cash", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities", "menuCat": "Details", "order": "31", "role": "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable", "shortName": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c36", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueNetAssetLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Fair Value Measurements (Details) - Schedule of changes in the fair value of the company\u2019s Level 3 financial liabilities", "menuCat": "Details", "order": "32", "role": "http://Amplitudehealthcare.com/role/ScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesTable", "shortName": "Fair Value Measurements (Details) - Schedule of changes in the fair value of the company\u2019s Level 3 financial liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c36", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueNetAssetLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Fair Value Measurements (Details) - Schedule of fair value measurements", "menuCat": "Details", "order": "33", "role": "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable", "shortName": "Fair Value Measurements (Details) - Schedule of fair value measurements", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c6", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Condensed Consolidated Balance Sheet Components (Details)", "menuCat": "Details", "order": "34", "role": "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponentsDetails", "shortName": "Condensed Consolidated Balance Sheet Components (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c6", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Condensed Consolidated Balance Sheet Components (Details) - Schedule of prepaid expenses and other current assets", "menuCat": "Details", "order": "35", "role": "http://Amplitudehealthcare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable", "shortName": "Condensed Consolidated Balance Sheet Components (Details) - Schedule of prepaid expenses and other current assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseholdImprovementsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Condensed Consolidated Balance Sheet Components (Details) - Schedule of property and equipment", "menuCat": "Details", "order": "36", "role": "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable", "shortName": "Condensed Consolidated Balance Sheet Components (Details) - Schedule of property and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseholdImprovementsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "jspr:ResearchAndDevelopmentAccruedExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Condensed Consolidated Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities", "menuCat": "Details", "order": "37", "role": "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable", "shortName": "Condensed Consolidated Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "jspr:ResearchAndDevelopmentAccruedExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Condensed Consolidated Balance Sheet Components (Details) - Schedule of other non-current liabilities", "menuCat": "Details", "order": "38", "role": "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable", "shortName": "Condensed Consolidated Balance Sheet Components (Details) - Schedule of other non-current liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c49", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Cirm Grant (Details)", "menuCat": "Details", "order": "39", "role": "http://Amplitudehealthcare.com/role/CirmGrantDetails", "shortName": "Cirm Grant (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "3", "lang": null, "name": "jspr:PercentageOfLicensingFees", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "jspr:AnnualLicenseMaintenanceFeesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Significant Agreements (Details)", "menuCat": "Details", "order": "40", "role": "http://Amplitudehealthcare.com/role/SignificantAgreementsDetails", "shortName": "Significant Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "jspr:AnnualLicenseMaintenanceFeesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeMaturityDates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Derivative Financial Instruments (Details)", "menuCat": "Details", "order": "41", "role": "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails", "shortName": "Derivative Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeMaturityDates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c47", "decimals": "0", "first": true, "lang": null, "name": "jspr:RentableSquareFeetWithLeaseCommencement", "reportCount": 1, "unique": true, "unitRef": "sqm", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "42", "role": "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c47", "decimals": "0", "first": true, "lang": null, "name": "jspr:RentableSquareFeetWithLeaseCommencement", "reportCount": 1, "unique": true, "unitRef": "sqm", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Commitments and Contingencies (Details) - Schedule of components of lease costs", "menuCat": "Details", "order": "43", "role": "http://Amplitudehealthcare.com/role/ScheduleofcomponentsofleasecostsTable", "shortName": "Commitments and Contingencies (Details) - Schedule of components of lease costs", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Commitments and Contingencies (Details) - Schedule of operating leases", "menuCat": "Details", "order": "44", "role": "http://Amplitudehealthcare.com/role/ScheduleofoperatingleasesTable", "shortName": "Commitments and Contingencies (Details) - Schedule of operating leases", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Commitments and Contingencies (Details) - Schedule of operating lease liabilities showing the aggregate lease payments", "menuCat": "Details", "order": "45", "role": "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable", "shortName": "Commitments and Contingencies (Details) - Schedule of operating lease liabilities showing the aggregate lease payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Common Stock (Details)", "menuCat": "Details", "order": "46", "role": "http://Amplitudehealthcare.com/role/CommonStockDetails", "shortName": "Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromSaleOfTreasuryStock", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "INF", "first": true, "lang": null, "name": "jspr:OutstandingAndIssuedCommonStockOption", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Common Stock (Details) - Schedule of common stock reserved for future issuance", "menuCat": "Details", "order": "47", "role": "http://Amplitudehealthcare.com/role/ScheduleofcommonstockreservedforfutureissuanceTable", "shortName": "Common Stock (Details) - Schedule of common stock reserved for future issuance", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c4", "decimals": "INF", "first": true, "lang": null, "name": "jspr:OutstandingAndIssuedCommonStockOption", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Stock-Based Compensation (Details)", "menuCat": "Details", "order": "48", "role": "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c68", "decimals": "INF", "first": true, "lang": null, "name": "jspr:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option activity", "menuCat": "Details", "order": "49", "role": "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "shortName": "Stock-Based Compensation (Details) - Schedule of stock option activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c68", "decimals": "INF", "first": true, "lang": null, "name": "jspr:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c5", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Stock-Based Compensation (Details) - Schedule of the performance-based stock options activity", "menuCat": "Details", "order": "50", "role": "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable", "shortName": "Stock-Based Compensation (Details) - Schedule of the performance-based stock options activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c5", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c71", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSUs activity", "menuCat": "Details", "order": "51", "role": "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable", "shortName": "Stock-Based Compensation (Details) - Schedule of RSUs activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c71", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "jspr:ResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense", "menuCat": "Details", "order": "52", "role": "http://Amplitudehealthcare.com/role/ScheduleofstockbasedcompensationexpenseTable", "shortName": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "jspr:ResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c73", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Stock-Based Compensation (Details) - Schedule of fair value of stock options was estimated using a Black-Scholes option-pricing model", "menuCat": "Details", "order": "53", "role": "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable", "shortName": "Stock-Based Compensation (Details) - Schedule of fair value of stock options was estimated using a Black-Scholes option-pricing model", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c73", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted net loss per share attributable to common stockholders", "menuCat": "Details", "order": "54", "role": "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted net loss per share attributable to common stockholders", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted net loss per share attributable to common stockholders (Parentheticals)", "menuCat": "Details", "order": "55", "role": "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable_Parentheticals", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted net loss per share attributable to common stockholders (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of diluted net loss per share attributable to common stockholders", "menuCat": "Details", "order": "56", "role": "http://Amplitudehealthcare.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of diluted net loss per share attributable to common stockholders", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "jspr:ConsultingServices", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-5", "first": true, "lang": null, "name": "jspr:ConsultingServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Related Parties (Details)", "menuCat": "Details", "order": "57", "role": "http://Amplitudehealthcare.com/role/RelatedPartiesDetails", "shortName": "Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "jspr:ConsultingServices", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-5", "first": true, "lang": null, "name": "jspr:ConsultingServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c16", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c16", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-5", "first": true, "lang": null, "name": "jspr:Issuanceofcommonstockthroughunderwrittenofferingnetofdiscountsandcommissionsandissuancecosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "7", "role": "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3_Parentheticals", "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-5", "first": true, "lang": null, "name": "jspr:Issuanceofcommonstockthroughunderwrittenofferingnetofdiscountsandcommissionsandissuancecosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "8", "role": "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Organization and Description of Business", "menuCat": "Notes", "order": "9", "role": "http://Amplitudehealthcare.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0323_jasperthera.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 24, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/SignificantAgreementsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/SignificantAgreementsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "jspr_AggregateIntrinsicValueExercisable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate Intrinsic Value Exercisable.", "label": "Aggregate Intrinsic Value Exercisable", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "AggregateIntrinsicValueExercisable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "monetaryItemType" }, "jspr_AggregateIntrinsicValueOptionCancelledforfeited": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options cancelled forfeited.", "label": "Aggregate Intrinsic Value Option Cancelledforfeited", "terseLabel": "Aggregate Intrinsic Value, Options cancelled/forfeited" } } }, "localname": "AggregateIntrinsicValueOptionCancelledforfeited", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "jspr_AggregateIntrinsicValueOptionExercised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options exercised.", "label": "Aggregate Intrinsic Value Option Exercised", "terseLabel": "Aggregate Intrinsic Value, Options exercised" } } }, "localname": "AggregateIntrinsicValueOptionExercised", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "jspr_AggregateIntrinsicValueOptionsGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award option granted under share-based payment arrangement. Excludes share and unit options.", "label": "Aggregate Intrinsic Value Options Granted", "terseLabel": "Aggregate Intrinsic Value, Options granted" } } }, "localname": "AggregateIntrinsicValueOptionsGranted", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "monetaryItemType" }, "jspr_AggregateIntrinsicValuesOptionsGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted.", "label": "Aggregate Intrinsic Values Options Granted", "terseLabel": "Aggregate Intrinsic Value, Options granted" } } }, "localname": "AggregateIntrinsicValuesOptionsGranted", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "jspr_AggregateOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate offering price.", "label": "Aggregate Offering Price", "terseLabel": "Aggregate offering price" } } }, "localname": "AggregateOfferingPrice", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "monetaryItemType" }, "jspr_AgreementForSquareFeetOfTemporaryOfficeSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement for square feet of temporary office space.", "label": "Agreement For Square Feet Of Temporary Office Space", "terseLabel": "Agreement for square feet (in Square Feet)" } } }, "localname": "AgreementForSquareFeetOfTemporaryOfficeSpace", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "areaItemType" }, "jspr_AnnualLicenseMaintenanceFeesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of annual license maintenance fees.", "label": "Annual License Maintenance Fees Description", "terseLabel": "Annual license maintenance fees, description" } } }, "localname": "AnnualLicenseMaintenanceFeesDescription", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/SignificantAgreementsDetails" ], "xbrltype": "stringItemType" }, "jspr_AvailableOfferingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of available offering.", "label": "Available Offering Amount", "terseLabel": "Available offering amount" } } }, "localname": "AvailableOfferingAmount", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "monetaryItemType" }, "jspr_CashCashEquivalentsAndRestrictedCashAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents And Restricted Cash Abstract", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsAndRestrictedCashAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "jspr_ChangeInFairValueOfEarnoutLiability": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OtherIncome", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of earnout liability.", "label": "Change In Fair Value Of Earnout Liability", "negatedLabel": "Change in fair value of earnout liability" } } }, "localname": "ChangeInFairValueOfEarnoutLiability", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "jspr_CirmGrantDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cirm Grant Details Line Items", "terseLabel": "Cirm Grant Disclosure [Abstract]" } } }, "localname": "CirmGrantDetailsLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails" ], "xbrltype": "stringItemType" }, "jspr_CirmGrantDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cirm Grant (Details) [Table]" } } }, "localname": "CirmGrantDetailsTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails" ], "xbrltype": "stringItemType" }, "jspr_CirmGrantDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cirm Grant Disclosure Abstract" } } }, "localname": "CirmGrantDisclosureAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_CirmGrantDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure about Cirm Grant.", "label": "Cirm Grant Disclosure Text Block", "terseLabel": "CIRM GRANT" } } }, "localname": "CirmGrantDisclosureTextBlock", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrant" ], "xbrltype": "textBlockItemType" }, "jspr_CirmGrantLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cirm Grant Disclosure [Abstract]" } } }, "localname": "CirmGrantLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrant" ], "xbrltype": "stringItemType" }, "jspr_CirmGrantTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cirm Grant [Table]" } } }, "localname": "CirmGrantTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrant" ], "xbrltype": "stringItemType" }, "jspr_CommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This amount of common stock value.", "label": "Common Stock", "terseLabel": "Common stock value" } } }, "localname": "CommonStock", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "monetaryItemType" }, "jspr_CommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Abstract]" } } }, "localname": "CommonStockAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_CommonStockDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Details) [Line Items]" } } }, "localname": "CommonStockDetailsLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "jspr_CommonStockDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock (Details) [Table]" } } }, "localname": "CommonStockDetailsTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "jspr_CommonStockPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of common stock means the closing price of the common stock on the last trading day immediately preceding the day as of which the common stock is to be valued. vesting shall not be taken into account in determining the value of common stock for this purpose.", "label": "Common Stock Price", "terseLabel": "Common stock price (in Dollars per share)" } } }, "localname": "CommonStockPrice", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable" ], "xbrltype": "perShareItemType" }, "jspr_CommonStockSharesOfVoting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of voting common stock.", "label": "Common Stock Shares Of Voting", "terseLabel": "Shares of voting common stock (in Shares)" } } }, "localname": "CommonStockSharesOfVoting", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "sharesItemType" }, "jspr_CommonStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure about common stock.", "label": "Common Stock Text Block", "terseLabel": "COMMON STOCK" } } }, "localname": "CommonStockTextBlock", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "jspr_CommonStockWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrants.", "label": "Common Stock Warrant", "terseLabel": "Common stock warrants" } } }, "localname": "CommonStockWarrant", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcommonstockreservedforfutureissuanceTable" ], "xbrltype": "sharesItemType" }, "jspr_CommonStockWarrantLiability": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of common stock warrant liability.", "label": "Common Stock Warrant Liability", "terseLabel": "Common stock warrant liability" } } }, "localname": "CommonStockWarrantLiability", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet", "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "jspr_CommonStockWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrants.", "label": "Common Stock Warrants", "terseLabel": "Common stock warrants" } } }, "localname": "CommonStockWarrants", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "jspr_CommonStockWarrantsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock warrants fair value.", "label": "Common Stock Warrants Fair Value", "terseLabel": "Common stock warrants fair value" } } }, "localname": "CommonStockWarrantsFairValue", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "jspr_CondensedConsolidatedBalanceSheetComponentsDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses and Other Current Liabilities [Abstract]" } } }, "localname": "CondensedConsolidatedBalanceSheetComponentsDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_CondensedConsolidatedBalanceSheetComponentsDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities [Table]" } } }, "localname": "CondensedConsolidatedBalanceSheetComponentsDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_CondensedConsolidatedBalanceSheetComponentsDetailsScheduleofothernoncurrentliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Other Non Current Liabilities [Abstract]" } } }, "localname": "CondensedConsolidatedBalanceSheetComponentsDetailsScheduleofothernoncurrentliabilitiesLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_CondensedConsolidatedBalanceSheetComponentsDetailsScheduleofothernoncurrentliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheet Components (Details) - Schedule of other non-current liabilities [Table]" } } }, "localname": "CondensedConsolidatedBalanceSheetComponentsDetailsScheduleofothernoncurrentliabilitiesTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_CondensedConsolidatedBalanceSheetComponentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheet Components [Abstract]" } } }, "localname": "CondensedConsolidatedBalanceSheetComponentsLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponents" ], "xbrltype": "stringItemType" }, "jspr_CondensedConsolidatedBalanceSheetComponentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheet Components [Table]" } } }, "localname": "CondensedConsolidatedBalanceSheetComponentsTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponents" ], "xbrltype": "stringItemType" }, "jspr_CondensedConsolidatedBalanceSheetComponentsTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheet Components Tables Line Items", "terseLabel": "Condensed Consolidated Balance Sheet Components [Abstract]" } } }, "localname": "CondensedConsolidatedBalanceSheetComponentsTablesLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponentsTables" ], "xbrltype": "stringItemType" }, "jspr_CondensedConsolidatedBalanceSheetComponentsTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheet Components (Tables) [Table]" } } }, "localname": "CondensedConsolidatedBalanceSheetComponentsTablesTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponentsTables" ], "xbrltype": "stringItemType" }, "jspr_ConsultingServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consulting services.", "label": "Consulting Services", "terseLabel": "Advisory and consulting services" } } }, "localname": "ConsultingServices", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "jspr_ContingentEarnoutLiabilitiesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent earnout liability.", "label": "Contingent Earnout Liabilities Description", "terseLabel": "Description of contingent earnout liability" } } }, "localname": "ContingentEarnoutLiabilitiesDescription", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "jspr_CurrentPortionOfLeaseLiability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of Current portion of lease liability.", "label": "Current Portion Of Lease Liability", "terseLabel": "Less current portion of lease liability" } } }, "localname": "CurrentPortionOfLeaseLiability", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "jspr_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator Abstract", "terseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "stringItemType" }, "jspr_DerivativeFinancialInstrumentsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments (Details) [Line Items]" } } }, "localname": "DerivativeFinancialInstrumentsDetailsLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "jspr_DerivativeFinancialInstrumentsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments (Details) [Table]" } } }, "localname": "DerivativeFinancialInstrumentsDetailsTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "jspr_DerivativeFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments [Abstract]" } } }, "localname": "DerivativeFinancialInstrumentsLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstruments" ], "xbrltype": "stringItemType" }, "jspr_DerivativeFinancialInstrumentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments [Table]" } } }, "localname": "DerivativeFinancialInstrumentsTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstruments" ], "xbrltype": "stringItemType" }, "jspr_DescriptionOfESPP": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of ESPP.", "label": "Description Of ESPP", "terseLabel": "Description of ESPP" } } }, "localname": "DescriptionOfESPP", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "jspr_DilutedNetLossPerShareAttributableToCommonStockholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diluted net loss per share attributable to common stockholders.", "label": "Diluted Net Loss Per Share Attributable To Common Stockholders", "totalLabel": "Total" } } }, "localname": "DilutedNetLossPerShareAttributableToCommonStockholders", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "jspr_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_EarnoutLiability": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of earnout liability.", "label": "Earnout Liability", "terseLabel": "Earnout liability" } } }, "localname": "EarnoutLiability", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "jspr_EarnoutLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnout Liability Member", "terseLabel": "Earnout Liability [Member]" } } }, "localname": "EarnoutLiabilityMember", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesTable" ], "xbrltype": "domainItemType" }, "jspr_ExercisePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price Member", "terseLabel": "Exercise Price [Member]" } } }, "localname": "ExercisePriceMember", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "jspr_ExpectedVolatility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected Volatility", "terseLabel": "Expected volatility" } } }, "localname": "ExpectedVolatility", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable" ], "xbrltype": "percentItemType" }, "jspr_FairMarketValueOfCommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair market value of common stock percentage.", "label": "Fair Market Value Of Common Stock Percentage", "terseLabel": "Fair market value of common stock percentage" } } }, "localname": "FairMarketValueOfCommonStockPercentage", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "jspr_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of changes in the fair value of the company\u2019s Level 3 financial liabilities [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of changes in the fair value of the company\u2019s Level 3 financial liabilities [Table]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities [Table]" } } }, "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_FinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Assets Abstract", "terseLabel": "Financial assets" } } }, "localname": "FinancialAssetsAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_FinancialLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Liabilities Abstract", "terseLabel": "Financial liabilities" } } }, "localname": "FinancialLiabilitiesAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "jspr_FirstMilestoneAgremment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First milestone agremment.", "label": "First Milestone Agremment", "terseLabel": "First milestone agreement paid" } } }, "localname": "FirstMilestoneAgremment", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "jspr_FundTechnology": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fund technology.", "label": "Fund Technology", "terseLabel": "CIRM fund technology" } } }, "localname": "FundTechnology", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails" ], "xbrltype": "monetaryItemType" }, "jspr_ISRAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ISRAMember", "terseLabel": "ISRA [Member]" } } }, "localname": "ISRAMember", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/SignificantAgreementsDetails" ], "xbrltype": "domainItemType" }, "jspr_ImprovementAllowanceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Improvement allowance,description.", "label": "Improvement Allowance Description", "terseLabel": "Improvement allowance, description" } } }, "localname": "ImprovementAllowanceDescription", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "jspr_IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of issuance of common stock through ATM offering, net of commissions and offering costs.", "label": "Issuance Of Common Stock Through ATMOffering Net Of Commissions And Offering Cost", "terseLabel": "Issuance of common stock through ATM offering, net of commissions and offering costs" } } }, "localname": "IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCost", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3_Parentheticals" ], "xbrltype": "monetaryItemType" }, "jspr_IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock through ATM offering, net of commissions.", "label": "Issuance Of Common Stock Through ATMOffering Net Of Commissions And Offering Costs", "terseLabel": "Issuance of common stock through ATM offering, net of commissions and offering costs of $0.1 million (in Shares)" } } }, "localname": "IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCosts", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "jspr_IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCostsOf01M": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock through ATM offering.", "label": "Issuance Of Common Stock Through ATMOffering Net Of Commissions And Offering Costs Of01 M", "terseLabel": "Issuance of common stock through ATM offering, net of commissions and offering costs of $0.1 million" } } }, "localname": "IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCostsOf01M", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "jspr_IssuanceOfCommonStockUponExerciseOfCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon exercise of common stock warrants.", "label": "Issuance Of Common Stock Upon Exercise Of Common Stock Warrants", "terseLabel": "Issuance of common stock upon exercise of common stock warrants" } } }, "localname": "IssuanceOfCommonStockUponExerciseOfCommonStockWarrants", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "jspr_IssuanceOfCommonStockUponExerciseOfCommonStockWarrantsinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon exercise of common stock warrants (in Shares).", "label": "Issuance Of Common Stock Upon Exercise Of Common Stock Warrantsin Shares", "terseLabel": "Issuance of common stock upon exercise of common stock warrants (in Shares)" } } }, "localname": "IssuanceOfCommonStockUponExerciseOfCommonStockWarrantsinShares", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "jspr_Issuanceofcommonstockthroughunderwrittenofferingnetofdiscountsandcommissionsandissuancecosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of issuance of common stock through underwritten offering, net of discounts and commissions and issuance costs.", "label": "Issuanceofcommonstockthroughunderwrittenofferingnetofdiscountsandcommissionsandissuancecosts", "terseLabel": "Issuance of common stock through underwritten offering, net of discounts and commissions and issuance costs" } } }, "localname": "Issuanceofcommonstockthroughunderwrittenofferingnetofdiscountsandcommissionsandissuancecosts", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3_Parentheticals" ], "xbrltype": "monetaryItemType" }, "jspr_LeaseholdImprovementGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvement to assets held under a lease arrangement.", "label": "Leasehold Improvement Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementGross", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "jspr_LessorAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessor amount.", "label": "Lessor Amount", "terseLabel": "Lessor amount" } } }, "localname": "LessorAmount", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "jspr_LicenseAgreementsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreements, description.", "label": "License Agreements Description", "terseLabel": "License agreements, description" } } }, "localname": "LicenseAgreementsDescription", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "jspr_MonteCarloValuationModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Monte Carlo Valuation Model Member", "terseLabel": "Monte Carlo valuation model [Member]", "verboseLabel": "Monte Carlo Simulation Model [Member]" } } }, "localname": "MonteCarloValuationModelMember", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "jspr_NetConstructionCostsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net construction costs, percentage.", "label": "Net Construction Costs Percentage", "terseLabel": "Net construction costs, percentage" } } }, "localname": "NetConstructionCostsPercentage", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "jspr_NonVotingCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non voting common stock.", "label": "Non Voting Common Stock", "terseLabel": "Non voting common stock" } } }, "localname": "NonVotingCommonStock", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "jspr_NoncurrentPortionOfLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present values of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Noncurrent Portion Of Lease Liability", "terseLabel": "Noncurrent portion of lease liability" } } }, "localname": "NoncurrentPortionOfLeaseLiability", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "jspr_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator Abstract", "terseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "stringItemType" }, "jspr_OperatingLeaseLiabilites": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating leases.", "label": "Operating Lease Liabilites", "totalLabel": "Total discounted lease payments" } } }, "localname": "OperatingLeaseLiabilites", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "jspr_OrganizationandDescriptionofBusinessLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Abstract]" } } }, "localname": "OrganizationandDescriptionofBusinessLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "stringItemType" }, "jspr_OrganizationandDescriptionofBusinessTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Table]" } } }, "localname": "OrganizationandDescriptionofBusinessTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "stringItemType" }, "jspr_OtherReceivablesMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables Milestone", "terseLabel": "Other receivables milestone" } } }, "localname": "OtherReceivablesMilestone", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails" ], "xbrltype": "monetaryItemType" }, "jspr_OutstandingAndIssuedCommonStockOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding and issued common stock options.", "label": "Outstanding And Issued Common Stock Option", "terseLabel": "Outstanding and issued common stock options" } } }, "localname": "OutstandingAndIssuedCommonStockOption", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcommonstockreservedforfutureissuanceTable" ], "xbrltype": "sharesItemType" }, "jspr_OutstandingRSUs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of restricted stock units outstanding.", "label": "Outstanding RSUs", "terseLabel": "Outstanding RSUs" } } }, "localname": "OutstandingRSUs", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "jspr_PayStanfordNet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pay stanford net.", "label": "Pay Stanford Net", "terseLabel": "Pay stanford net" } } }, "localname": "PayStanfordNet", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "jspr_PayStanfordNetTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pay stanford net term.", "label": "Pay Stanford Net Term", "terseLabel": "Pay stanford net term" } } }, "localname": "PayStanfordNetTerm", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "jspr_PercentageOfLicensingFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "licensing fees.", "label": "Percentage Of Licensing Fees", "terseLabel": "Percentage of licensing fees" } } }, "localname": "PercentageOfLicensingFees", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails" ], "xbrltype": "percentItemType" }, "jspr_ProceedsFromIssuanceOfCommonStockThroughATMAndUnderwritingOfferingsNet": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock.", "label": "Proceeds From Issuance Of Common Stock Through ATMAnd Underwriting Offerings Net", "terseLabel": "Proceeds from issuance of common stock through ATM and underwritten offerings, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStockThroughATMAndUnderwritingOfferingsNet", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "jspr_ReceivedAggregateFromCIRM": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Received Aggregate From CIRM", "terseLabel": "Received aggregate from CIRM" } } }, "localname": "ReceivedAggregateFromCIRM", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails" ], "xbrltype": "monetaryItemType" }, "jspr_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Voting Common Stock At An Exercise Price Of1150 Member", "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50" } } }, "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtAnExercisePriceOf1150Member", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "jspr_RentableSquareFeetWithLeaseCommencement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rentable square feet with lease commencement.", "label": "Rentable Square Feet With Lease Commencement", "terseLabel": "Rentable square feet (in Square Meters)" } } }, "localname": "RentableSquareFeetWithLeaseCommencement", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "areaItemType" }, "jspr_ResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofstockbasedcompensationexpenseTable": { "order": 1.0, "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development.", "label": "Research And Development", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopment", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "monetaryItemType" }, "jspr_ResearchAndDevelopmentAccruedExpenses": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research and development accrued expenses.", "label": "Research And Development Accrued Expenses", "terseLabel": "Research and development accrued expenses" } } }, "localname": "ResearchAndDevelopmentAccruedExpenses", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "jspr_RestrictedStockLiabilities": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of restricted stock liabilities.", "label": "Restricted Stock Liabilities", "terseLabel": "Restricted stock liability" } } }, "localname": "RestrictedStockLiabilities", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "jspr_RiskfreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Riskfree Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "RiskfreeInterestRate", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable" ], "xbrltype": "percentItemType" }, "jspr_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Accrued Expenses And Other Current Liabilities Abstract" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Abstract]" } } }, "localname": "ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfChangesInTheFairValueOfTheCompanySLevel3FinancialLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Changes In The Fair Value Of The Company SLevel3 Financial Liabilities Abstract" } } }, "localname": "ScheduleOfChangesInTheFairValueOfTheCompanySLevel3FinancialLiabilitiesAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfCommonStockReservedForFutureIssuanceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Common Stock Reserved For Future Issuance Abstract" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfComponentsOfLeaseCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Components Of Lease Costs Abstract" } } }, "localname": "ScheduleOfComponentsOfLeaseCostsAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Abstract]" } } }, "localname": "ScheduleOfDilutedNetLossPerShareAttributableToCommonStockholdersAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfFairValueMeasurementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Measurements Abstract" } } }, "localname": "ScheduleOfFairValueMeasurementsAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of Stock Options Was Estimated Using ABlack Scholes Option Pricing Model Abstract" } } }, "localname": "ScheduleOfFairValueOfStockOptionsWasEstimatedUsingABlackScholesOptionPricingModelAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfFinancialAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Financial Assets And Liabilities Abstract" } } }, "localname": "ScheduleOfFinancialAssetsAndLiabilitiesAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]" } } }, "localname": "ScheduleOfOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfOperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Operating Leases [Abstract]" } } }, "localname": "ScheduleOfOperatingLeasesAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfOtherNonCurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Other Non Current Liabilities Abstract" } } }, "localname": "ScheduleOfOtherNonCurrentLiabilitiesAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Prepaid Expenses And Other Current Assets Abstract" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfPropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Abstract" } } }, "localname": "ScheduleOfPropertyAndEquipmentAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash [Abstract]" } } }, "localname": "ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfRsusActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Rsus Activity Abstract" } } }, "localname": "ScheduleOfRsusActivityAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfStockBasedCompensationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Stock Based Compensation Expense Abstract" } } }, "localname": "ScheduleOfStockBasedCompensationExpenseAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfStockOptionActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Stock Option Activity Abstract" } } }, "localname": "ScheduleOfStockOptionActivityAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ScheduleOfThePerformanceBasedStockOptionsActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of The Performance Based Stock Options Activity Abstract" } } }, "localname": "ScheduleOfThePerformanceBasedStockOptionsActivityAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentWeightedAverageGrantDateFairValueVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Grant date Fair Value, Vested.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Weighted Average Grant Date Fair Value Vested", "terseLabel": "Weighted Average Grant date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentWeightedAverageGrantDateFairValueVested", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable" ], "xbrltype": "perShareItemType" }, "jspr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Balance Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingIntrinsicValue", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "jspr_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payments Award Options Outstanding Number", "terseLabel": "Number of Shares, Balance Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsOutstandingNumber", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "sharesItemType" }, "jspr_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payments Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Balance Ending", "periodStartLabel": "Weighted Average Exercise Price, Balance Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "perShareItemType" }, "jspr_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable" ], "xbrltype": "durationItemType" }, "jspr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term", "terseLabel": "Weighted - Average Remaining Contractual Life (Years), Balance Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "durationItemType" }, "jspr_SharebasedCompensationArrangementBySharebasedPaymentWeightedAverageGrantdateFairValueOutstandingrestrictedstockunitsatendingbalan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Weighted Average Grantdate Fair Value Outstandingrestrictedstockunitsatendingbalan", "terseLabel": "Weighted Average Grant date Fair Value, Outstanding restricted stock units at ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentWeightedAverageGrantdateFairValueOutstandingrestrictedstockunitsatendingbalan", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable" ], "xbrltype": "perShareItemType" }, "jspr_SharesAvailableForGrantBalanceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options granted.", "label": "Shares Available For Grant Balance Ending", "terseLabel": "Number of Shares, Balance Ending" } } }, "localname": "SharesAvailableForGrantBalanceEnding", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "sharesItemType" }, "jspr_SharesAvailableForGrantUnder2019EquityIncentivePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares available for grant under 2019 Equity Incentive Plan.", "label": "Shares Available For Grant Under2019 Equity Incentive Plan", "terseLabel": "Shares available for grant under 2022 Inducement Equity Incentive Plan" } } }, "localname": "SharesAvailableForGrantUnder2019EquityIncentivePlan", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcommonstockreservedforfutureissuanceTable" ], "xbrltype": "sharesItemType" }, "jspr_SharesAvailableForGrantUnder2021EmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares available for grant under 2021 Employee Stock Purchase Plan.", "label": "Shares Available For Grant Under2021 Employee Stock Purchase Plan", "terseLabel": "Shares available for grant under 2021 Employee Stock Purchase Plan" } } }, "localname": "SharesAvailableForGrantUnder2021EmployeeStockPurchasePlan", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcommonstockreservedforfutureissuanceTable" ], "xbrltype": "sharesItemType" }, "jspr_SharesAvailableForGrantUnder2021EquityIncentivePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares available for grant under 2021 Equity Incentive Plan.", "label": "Shares Available For Grant Under2021 Equity Incentive Plan", "terseLabel": "Shares available for grant under 2021 Equity Incentive Plan" } } }, "localname": "SharesAvailableForGrantUnder2021EquityIncentivePlan", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcommonstockreservedforfutureissuanceTable" ], "xbrltype": "sharesItemType" }, "jspr_SharesOfNonvotingCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of non-voting common stock.", "label": "Shares Of Nonvoting Common Stock", "terseLabel": "Shares of non-voting common stock (in Shares)" } } }, "localname": "SharesOfNonvotingCommonStock", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "sharesItemType" }, "jspr_SignificantAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Agreements [Abstract]" } } }, "localname": "SignificantAgreementsAbstract", "nsuri": "http://Amplitudehealthcare.com/20230331", "xbrltype": "stringItemType" }, "jspr_SignificantAgreementsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Agreements (Details) [Line Items]" } } }, "localname": "SignificantAgreementsDetailsLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/SignificantAgreementsDetails" ], "xbrltype": "stringItemType" }, "jspr_SignificantAgreementsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Agreements (Details) [Table]" } } }, "localname": "SignificantAgreementsDetailsTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/SignificantAgreementsDetails" ], "xbrltype": "stringItemType" }, "jspr_SignificantAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure about significant agreements.", "label": "Significant Agreements Text Block", "terseLabel": "SIGNIFICANT AGREEMENTS" } } }, "localname": "SignificantAgreementsTextBlock", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/SignificantAgreements" ], "xbrltype": "textBlockItemType" }, "jspr_StockBasedCompensationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Line Items]" } } }, "localname": "StockBasedCompensationDetailsLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "jspr_StockBasedCompensationDetailsScheduleofRSUsactivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of RSUs activity [Line Items]" } } }, "localname": "StockBasedCompensationDetailsScheduleofRSUsactivityLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable" ], "xbrltype": "stringItemType" }, "jspr_StockBasedCompensationDetailsScheduleofRSUsactivityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of RSUs activity [Table]" } } }, "localname": "StockBasedCompensationDetailsScheduleofRSUsactivityTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable" ], "xbrltype": "stringItemType" }, "jspr_StockBasedCompensationDetailsScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of fair value of stock options was estimated using a Black-Scholes option-pricing model [Line Items]" } } }, "localname": "StockBasedCompensationDetailsScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "stringItemType" }, "jspr_StockBasedCompensationDetailsScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of fair value of stock options was estimated using a Black-Scholes option-pricing model [Table]" } } }, "localname": "StockBasedCompensationDetailsScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "stringItemType" }, "jspr_StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of stock option activity [Line Items]" } } }, "localname": "StockBasedCompensationDetailsScheduleofstockoptionactivityLineItems", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "stringItemType" }, "jspr_StockBasedCompensationDetailsScheduleofstockoptionactivityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of stock option activity [Table]" } } }, "localname": "StockBasedCompensationDetailsScheduleofstockoptionactivityTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "stringItemType" }, "jspr_StockBasedCompensationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Table]" } } }, "localname": "StockBasedCompensationDetailsTable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "jspr_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options Member", "terseLabel": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "jspr_TotalSharesOfCommonStockReserved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total shares of common stock reserved.", "label": "Total Shares Of Common Stock Reserved", "terseLabel": "Total shares of common stock reserved" } } }, "localname": "TotalSharesOfCommonStockReserved", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcommonstockreservedforfutureissuanceTable" ], "xbrltype": "sharesItemType" }, "jspr_TwoZeroTwoTwoInducementPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Zero Two Two Inducement Plan Member", "terseLabel": "2022 Inducement Plan [Member]" } } }, "localname": "TwoZeroTwoTwoInducementPlanMember", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "jspr_UnderwritingAgreementPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting agreement price.", "label": "Underwriting Agreement Price", "terseLabel": "Underwriting agreement price (in Dollars per share)" } } }, "localname": "UnderwritingAgreementPrice", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "perShareItemType" }, "jspr_UnpaidOfferingsIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "unpaid offerings issuance costs included in accounts payable and accrued expenses.", "label": "Unpaid Offerings Issuance Costs Included In Accounts Payable And Accrued Expenses", "terseLabel": "Unpaid offerings issuance costs included in accrued expenses and other current liabilities" } } }, "localname": "UnpaidOfferingsIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "jspr_UnvestedRestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted common stock.", "label": "Unvested Restricted Common Stock", "terseLabel": "Unvested restricted common stock" } } }, "localname": "UnvestedRestrictedCommonStock", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "jspr_ValuationMethodology": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A valuation approach is the methodology used to determine the fair market value of a business.", "label": "Valuation Methodology", "terseLabel": "Valuation methodology" } } }, "localname": "ValuationMethodology", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable" ], "xbrltype": "stringItemType" }, "jspr_ValuationOfESPPAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Valuation Of ESPPAwards Member", "terseLabel": "Valuation of ESPP Awards [Member]" } } }, "localname": "ValuationOfESPPAwardsMember", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "domainItemType" }, "jspr_VestingOfFoundersRestrictedStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Vesting of founders restricted stock.", "label": "Vesting Of Founders Restricted Stock", "terseLabel": "Vesting of founders\u2019 restricted stock" } } }, "localname": "VestingOfFoundersRestrictedStock", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "jspr_VotingCommonStockParValue00001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Voting Common Stock Par Value00001 Per Share Member", "terseLabel": "Voting Common Stock, par value $0.0001 per share" } } }, "localname": "VotingCommonStockParValue00001PerShareMember", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "jspr_WeightedAverageRemainingContractualLifeYearsEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted - Average Remaining Contractual Life (Years) ending.", "label": "Weighted Average Remaining Contractual Life Years Ending", "terseLabel": "Weighted-Average Remaining Contractual Life (Years), Ending Balance" } } }, "localname": "WeightedAverageRemainingContractualLifeYearsEnding", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "durationItemType" }, "jspr_WeightedAverageRemainingContractualLifeYearsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted - Average Remaining Contractual Life (Years Exercisable).", "label": "Weighted Average Remaining Contractual Life Years Exercisable", "terseLabel": "Weighted-Average Remaining Contractual Life (Years), Exercisable" } } }, "localname": "WeightedAverageRemainingContractualLifeYearsExercisable", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "durationItemType" }, "jspr_WeightedAverageRemainingContractualLifeYearsOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted Average Remaining Contractual Life Years Options Granted", "terseLabel": "Weighted-Average Remaining Contractual Life (Years), Options granted" } } }, "localname": "WeightedAverageRemainingContractualLifeYearsOptionsGranted", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "durationItemType" }, "jspr_stockBasedCompensationForUnvestedOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock based compensation for unvested options.", "label": "stock Based Compensation For Unvested Options", "terseLabel": "stock-based compensation for unvested options" } } }, "localname": "stockBasedCompensationForUnvestedOptions", "nsuri": "http://Amplitudehealthcare.com/20230331", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Financial Information Disclosure [Abstract]" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "nsuri": "http://fasb.org/srt/2023", "xbrltype": "stringItemType" }, "srt_CondensedFinancialStatementsTextBlock": { "auth_ref": [ "r106", "r135" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for condensed financial statements.", "label": "Condensed Financial Statements [Text Block]", "terseLabel": "CONDENSED CONSOLIDATED BALANCE SHEET COMPONENTS" } } }, "localname": "CondensedFinancialStatementsTextBlock", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "srt_MaximumMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r234", "r329", "r360", "r390", "r391", "r450", "r452", "r455", "r456", "r465", "r476", "r477", "r486", "r493", "r497", "r503", "r554", "r563", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r234", "r329", "r360", "r390", "r391", "r450", "r452", "r455", "r456", "r465", "r476", "r477", "r486", "r493", "r497", "r503", "r554", "r563", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r191", "r192", "r193", "r194", "r226", "r234", "r260", "r261", "r262", "r328", "r329", "r360", "r390", "r391", "r450", "r452", "r455", "r456", "r465", "r476", "r477", "r486", "r493", "r497", "r503", "r506", "r550", "r554", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r226", "r234", "r260", "r261", "r262", "r328", "r329", "r360", "r390", "r391", "r450", "r452", "r455", "r456", "r465", "r476", "r477", "r486", "r493", "r497", "r503", "r506", "r550", "r554", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r149", "r235", "r524", "r542" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable", "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable", "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable", "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r149", "r235", "r524", "r525", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable", "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable", "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable", "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r18", "r502" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedCapitalizedInterestCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis.", "label": "Accumulated Capitalized Interest Costs", "terseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedCapitalizedInterestCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r113", "r354" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r65", "r502", "r574" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r269", "r270", "r271", "r376", "r539", "r540", "r541", "r556", "r575" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r264", "r272" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r88", "r115", "r134", "r172", "r180", "r182", "r186", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r278", "r282", "r299", "r347", "r414", "r502", "r514", "r552", "r553", "r561" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r109", "r121", "r134", "r186", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r278", "r282", "r299", "r502", "r552", "r553", "r561" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total fair value of assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable", "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalUnitsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of capital units or capital shares outstanding. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital Units, Outstanding", "terseLabel": "Outstanding restricted stock units" } } }, "localname": "CapitalUnitsOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcommonstockreservedforfutureissuanceTable" ], "xbrltype": "sharesItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r577" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Computer equipment" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareNet": { "auth_ref": [ "r478" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.", "label": "Capitalized Computer Software, Net", "terseLabel": "Capitalized software" } } }, "localname": "CapitalizedComputerSoftwareNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r96", "r349", "r387", "r408", "r502", "r514", "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r28", "r111", "r479" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents, at Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet", "http://Amplitudehealthcare.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r29", "r87" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r28", "r74", "r132" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r1", "r74" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r527", "r571" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofreconciliationofcashandcashequivalentsandrestrictedcashTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental and non-cash items reconciliations:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "terseLabel": "Change in the fair value included in other income (expense)" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r105", "r116", "r117", "r118", "r134", "r153", "r154", "r161", "r163", "r170", "r171", "r186", "r195", "r197", "r198", "r199", "r202", "r203", "r220", "r221", "r222", "r223", "r224", "r299", "r367", "r368", "r369", "r370", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r388", "r400", "r423", "r444", "r470", "r471", "r472", "r473", "r474", "r522", "r536", "r543" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r25", "r57", "r348", "r399" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note XX)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r80", "r189", "r190", "r475", "r551" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r504", "r505", "r506", "r508", "r509", "r510", "r511", "r539", "r540", "r556", "r572", "r575" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails", "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r64", "r400" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock, shares issued (in Shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails", "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r64", "r400", "r420", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r64", "r351", "r502" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock: $0.0001 par value \u2014 XX shares authorized at March 31, 2023 and December 31, 2022; XX and 38,045,677 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r30", "r31", "r32" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Issued of aggregate of shares (in Shares)" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentRate": { "auth_ref": [ "r30", "r32" ], "lang": { "en-us": { "role": { "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.", "label": "Debt Conversion, Converted Instrument, Rate", "terseLabel": "Percentage of converted loan" } } }, "localname": "DebtConversionConvertedInstrumentRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r61", "r62", "r89", "r90", "r135", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r307", "r488", "r489", "r490", "r491", "r492", "r537" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Option exercise fee" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/SignificantAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r23", "r135", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r307", "r488", "r489", "r490", "r491", "r492", "r537" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Offering cost" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The price per share or unit times the number of shares or units issued in an insurance entity stock offering in connection with its conversion from a mutual form of ownership to a stock entity. Amount is gross, before offering costs.", "label": "Demutualization by Insurance Entity, Securities Issued, Gross Cash Proceeds", "terseLabel": "Total net proceeds" } } }, "localname": "DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r5", "r39" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Fair value (in Dollars)" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r389", "r391", "r405", "r406", "r407", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r432", "r433", "r434", "r435", "r438", "r439", "r440", "r441", "r457", "r459", "r462", "r464", "r504", "r506" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r50", "r51", "r52", "r54", "r389", "r391", "r405", "r406", "r407", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r432", "r433", "r434", "r435", "r438", "r439", "r440", "r441", "r457", "r459", "r462", "r464", "r481", "r504", "r506" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r85", "r284", "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE FINANCIAL INSTRUMENTS" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r122" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "terseLabel": "CIRM grant liability" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeMaturityDates": { "auth_ref": [ "r390", "r391", "r457", "r458", "r460", "r461", "r463", "r506" ], "lang": { "en-us": { "role": { "documentation": "Date derivative contract ends, in YYYY-MM-DD format.", "label": "Derivative, Contract End Date", "terseLabel": "Expire date" } } }, "localname": "DerivativeMaturityDates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DirectTaxesAndLicensesCosts": { "auth_ref": [ "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax incurred and cost of license directly related to good produced or service rendered.", "label": "Cost, Direct Tax and License", "terseLabel": "License maintenance fee" } } }, "localname": "DirectTaxesAndLicensesCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r236", "r237", "r265", "r266", "r268", "r498" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r128", "r141", "r142", "r143", "r144", "r145", "r151", "r153", "r161", "r162", "r163", "r167", "r294", "r295", "r343", "r358", "r482" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)", "verboseLabel": "Net loss per share attributable to common stockholders \u2013 basic (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement", "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r128", "r141", "r142", "r143", "r144", "r145", "r153", "r161", "r162", "r163", "r167", "r294", "r295", "r343", "r358", "r482" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted", "verboseLabel": "Net loss per share attributable to common stockholders diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement_Parentheticals", "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r34", "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r150", "r164", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/NetLossPerShareAttributabletoCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee and related compensation expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "terseLabel": "Performance-based stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Options Outstanding [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPFairValueOfSharesSubjectToRepurchaseObligation": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the shares allocated that are subject to a repurchase obligation.", "label": "Employee Stock Ownership Plan (ESOP), Fair Value of Shares Subject to Repurchase Obligation", "terseLabel": "Employee Stock Ownership Plan (ESOP), Fair Value of Shares Subject to Repurchase Obligation" } } }, "localname": "EmployeeStockOwnershipPlanESOPFairValueOfSharesSubjectToRepurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r107", "r125", "r126", "r127", "r136", "r137", "r138", "r140", "r146", "r148", "r169", "r187", "r188", "r225", "r269", "r270", "r271", "r275", "r276", "r285", "r286", "r287", "r288", "r289", "r290", "r293", "r300", "r301", "r302", "r303", "r304", "r305", "r317", "r361", "r362", "r363", "r376", "r444" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails", "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityFairValueAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.", "label": "Equity, Fair Value Adjustment", "terseLabel": "Fair value equity" } } }, "localname": "EquityFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.", "label": "Equity Method Investment, Quoted Market Value", "terseLabel": "Fair value of common stock" } } }, "localname": "EquityMethodInvestmentQuotedMarketValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r0", "r5" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_OtherIncome", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of common stock warrant liability", "terseLabel": "Change in fair value of common stock warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow", "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Fair Value Measurements [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvaluemeasurementsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of fair value measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r212", "r227", "r228", "r229", "r230", "r231", "r232", "r298", "r325", "r326", "r327", "r489", "r490", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r212", "r227", "r232", "r298", "r325", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r212", "r227", "r232", "r298", "r326", "r489", "r490", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r212", "r227", "r228", "r229", "r230", "r231", "r232", "r298", "r327", "r489", "r490", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r212", "r227", "r228", "r229", "r230", "r231", "r232", "r325", "r326", "r327", "r489", "r490", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Fair Value, Net Asset (Liability)", "periodEndLabel": "Fair value, as of ending", "periodStartLabel": "Fair value, as of beginning", "totalLabel": "Total fair value of financial liabilities" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesTable", "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r79" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Office furniture & fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "terseLabel": "Recognized gain (loss)" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r72", "r426" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Payroll tax credit receivable" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r4" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": { "auth_ref": [ "r533" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other.", "label": "Increase (Decrease) in Accounts Receivable and Other Operating Assets", "negatedLabel": "Other receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r533" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r526", "r533" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r533" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r533" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r4" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OtherIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Other Income", "terseLabel": "Interest income" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r93" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OtherIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Other expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentInterestRate": { "auth_ref": [ "r450", "r451", "r452", "r453", "r454", "r455", "r465", "r466", "r506", "r545", "r546" ], "lang": { "en-us": { "role": { "documentation": "Rate of interest on investment.", "label": "Investment Interest Rate", "terseLabel": "Received from interest rate" } } }, "localname": "InvestmentInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r310", "r501" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofcomponentsofleasecostsTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcomponentsofleasecostsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcomponentsofleasecostsTable" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of components of lease costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r79" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of operating lease liabilities showing the aggregate lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r315" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023 (remainder of the year)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r315" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r315" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r315" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r315" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable": { "order": 1.0, "parentTag": "jspr_OperatingLeaseLiabilites", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r134", "r186", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r279", "r282", "r283", "r299", "r398", "r483", "r514", "r552", "r561", "r562" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r69", "r91", "r353", "r502", "r538", "r547", "r557" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r110", "r134", "r186", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r279", "r282", "r283", "r299", "r502", "r552", "r561", "r562" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueAdjustment": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.", "label": "Liabilities, Fair Value Adjustment", "negatedLabel": "Change in fair value of earnout liability" } } }, "localname": "LiabilitiesFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r79" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Lab equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r98", "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Weighted average period until annuitization or benefit payment is expected to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining", "terseLabel": "Weighted-average period" } } }, "localname": "NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r131" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r131" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r75", "r76" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r70", "r76", "r92", "r108", "r123", "r124", "r127", "r134", "r139", "r141", "r142", "r143", "r144", "r147", "r148", "r159", "r172", "r179", "r181", "r183", "r186", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r295", "r299", "r357", "r422", "r442", "r443", "r484", "r512", "r552" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss and comprehensive loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow", "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement", "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r129", "r152", "r155", "r156", "r157", "r158", "r160", "r163" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to common stockholders (in Dollars)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r172", "r179", "r181", "r183", "r484" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r311", "r501" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofcomponentsofleasecostsTable": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcomponentsofleasecostsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "auth_ref": [ "r168", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income, Lease Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities (in thousands)" } } }, "localname": "OperatingLeaseLeaseIncomeLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleasesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r309" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r309" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r308" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r534" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r314", "r501" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleasesTable" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r313", "r501" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleasesTable" ], "xbrltype": "durationItemType" }, "us-gaap_OptionContractIndexedToEquitySettlementCashEffectOfChangeInFairValueOfShare": { "auth_ref": [ "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash that would be paid upon settlement from change in fair value of share for option contract indexed to equity.", "label": "Option Contract Indexed to Equity, Settlement, Cash, Effect of Change in Fair Value of Share", "terseLabel": "Fair value of option" } } }, "localname": "OptionContractIndexedToEquitySettlementCashEffectOfChangeInFairValueOfShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionContractIndexedToEquitySettlementShareFairValue": { "auth_ref": [ "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of shares that would be issued upon settlement of option contract indexed to equity.", "label": "Option Contract Indexed to Equity, Settlement, Share, Fair Value", "terseLabel": "Fair value of option" } } }, "localname": "OptionContractIndexedToEquitySettlementShareFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r120", "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other prepaid expenses and current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r114" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r5", "r39", "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "terseLabel": "Depreciation and amortization expenses" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r359", "r424", "r467", "r468", "r469" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "totalLabel": "Total other (expense) income, net" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r56", "r346", "r394", "r395", "r514", "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "terseLabel": "Earnout liability" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffinancialassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months.", "label": "Other Liabilities and Deferred Revenue, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesAndDeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r20", "r502" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r24" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet", "http://Amplitudehealthcare.com/role/ScheduleofothernoncurrentliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Schedule of other non-current liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Operating cash flows" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r119", "r409" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofstockbasedcompensationexpenseTable": { "order": 2.0, "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expense classified as other.", "label": "Other Selling, General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "OtherSellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent", "terseLabel": "Temporary office space rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "auth_ref": [ "r73" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of machinery and equipment.", "label": "Payments to Acquire Machinery and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquireMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsShares": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.", "label": "Preferred Stock Dividends, Shares", "terseLabel": "Shares of undesignated preferred stock (in Shares)" } } }, "localname": "PreferredStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r504", "r505", "r508", "r509", "r510", "r511", "r572", "r575" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r63", "r220" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r63", "r400" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r63", "r220" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r63", "r400", "r420", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r63", "r350", "r502" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock: $0.0001 par value \u2014 XX shares authorized at March 31, 2023 and December 31, 2022; none issued and outstanding at March 31, 2023 and December 31, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r529" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet", "http://Amplitudehealthcare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r480", "r487", "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r2", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Reclassification of common stock warrant liability to equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r27", "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Right-of-use asset obtained in exchange for lease liabilities" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfTreasuryStock": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.", "label": "Proceeds from Sale of Treasury Stock", "terseLabel": "Sale of stock" } } }, "localname": "ProceedsFromSaleOfTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r2", "r15" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r108", "r123", "r124", "r130", "r134", "r139", "r147", "r148", "r172", "r179", "r181", "r183", "r186", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r277", "r280", "r281", "r295", "r299", "r344", "r356", "r375", "r422", "r442", "r443", "r484", "r499", "r500", "r513", "r530", "r552" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Incurred net losses" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r79", "r112", "r355" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Property and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r345", "r355", "r502" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet", "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r233", "r321", "r322", "r393", "r394", "r395", "r396", "r397", "r419", "r421", "r449" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r233", "r321", "r322", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r393", "r394", "r395", "r396", "r397", "r419", "r421", "r449", "r560" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r318", "r319", "r320", "r322", "r323", "r372", "r373", "r374", "r427", "r428", "r429", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTIES" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/RelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "terseLabel": "Fair market value percentage" } } }, "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r59", "r273", "r569" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r555" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development prepaid expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "auth_ref": [ "r60", "r555" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.", "label": "Research and Development Expense, Software (Excluding Acquired in Process Cost)", "terseLabel": "Research project related cost", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CirmGrantDetails", "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r527", "r535", "r570", "r571" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofreconciliationofcashandcashequivalentsandrestrictedcashTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r28", "r87", "r111", "r132", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofreconciliationofcashandcashequivalentsandrestrictedcashTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r97", "r528", "r535" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r66", "r81", "r352", "r364", "r365", "r371", "r401", "r502" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r107", "r136", "r137", "r138", "r140", "r146", "r148", "r187", "r188", "r269", "r270", "r271", "r275", "r276", "r285", "r287", "r288", "r290", "r293", "r361", "r363", "r376", "r575" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share (in Dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CondensedConsolidatedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of changes in the fair value of the company\u2019s Level 3 financial liabilities" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Schedule of common stock reserved for future issuance" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of operating leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r16", "r87", "r571" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of reconciliation of cash and cash equivalents and restricted cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of RSUs activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r13", "r14", "r44" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of the performance-based stock options activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of fair value of stock options was estimated using a Black-Scholes option-pricing model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in stock options.", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "terseLabel": "Schedule of the performance-based stock options activity" } } }, "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178", "r184", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r4" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofstockbasedcompensationexpenseTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Share-Based Payment Arrangement, Accelerated Cost", "totalLabel": "Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockbasedcompensationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r41", "r43" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "terseLabel": "Equity incentive plan, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Number of Shares, Outstanding restricted stock units at ending balance", "verboseLabel": "Restricted stock units (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Shares, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Granted amount (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r10", "r11" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "terseLabel": "Outstanding stock option (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Future grant (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of Shares,Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "netLabel": "Weighted-average exercise price (in Dollars per share)", "terseLabel": "Weighted Average Exercise Price, Exercisable", "verboseLabel": "Weighted Average Exercise Price, Exercisable (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares, Options cancelled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Shares, Options granted", "verboseLabel": "Options Outstanding, Options granted (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Balance Beginning", "verboseLabel": "Total intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodStartLabel": "Options Outstanding, Beginning balance (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance (in Dollars per share)", "periodStartLabel": "Weighted Average Exercise Price, Beginning balance (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "periodEndLabel": "Options Outstanding, Ending Balance", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest", "verboseLabel": "Aggregate Intrinsic Value, Vested and expected to vest, December 31, 2022" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options Outstanding, Exercisable (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance", "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "netLabel": "Number of Shares, Vested and unreleased", "terseLabel": "Number of Shares, Vested and expected to vest", "verboseLabel": "Options Outstanding, Vested and expected to vest, December 31, 2022 (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable", "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest, December 31, 2022 (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options cancelled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options granted", "verboseLabel": "Weighted Average Exercise Price, Options granted (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleoffairvalueofstockoptionswasestimatedusingaBlackScholesoptionpricingmodelTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted - Average Remaining Contractual Life (Years), Exercisable", "verboseLabel": "Weighted-Average Remaining Contractual Life (Years), Beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Number of Shares, Unvested restricted stock at ending balance", "periodStartLabel": "Number of Shares, Unvested restricted stock units at beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Grant date Fair Value, Unvested restricted stock units at ending balance", "periodStartLabel": "Weighted Average Grant date Fair Value, Unvested restricted stock units at beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted - Average Remaining Contractual Life (Years), Balance Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted - Average Remaining Contractual Life (Years), Vested and expected to vest", "verboseLabel": "Weighted-Average Remaining Contractual Life (Years), Vested and expected to vest, December 31, 2022" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/ScheduleoftheperformancebasedstockoptionsactivityTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "RSUs vested (in Shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "netLabel": "Weighted-average grant date fair value price (in Dollars per share)", "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest", "verboseLabel": "Weighted Average Grant date Fair Value, Vested and unreleased" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofRSUsactivityTable", "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Granted percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Share issued (in Shares)", "verboseLabel": "Issuance of share (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r312", "r501" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofcomponentsofleasecostsTable": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofcomponentsofleasecostsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r77", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r105", "r116", "r117", "r118", "r134", "r153", "r154", "r161", "r163", "r170", "r171", "r186", "r195", "r197", "r198", "r199", "r202", "r203", "r220", "r221", "r222", "r223", "r224", "r299", "r367", "r368", "r369", "r370", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r388", "r400", "r423", "r444", "r470", "r471", "r472", "r473", "r474", "r522", "r536", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/DocumentAndEntityInformation", "http://Amplitudehealthcare.com/role/ScheduleofchangesinthefairvalueofthecompanysLevel3financialliabilitiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r26", "r107", "r125", "r126", "r127", "r136", "r137", "r138", "r140", "r146", "r148", "r169", "r187", "r188", "r225", "r269", "r270", "r271", "r275", "r276", "r285", "r286", "r287", "r288", "r289", "r290", "r293", "r300", "r301", "r302", "r303", "r304", "r305", "r317", "r361", "r362", "r363", "r376", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails", "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r136", "r137", "r138", "r169", "r330", "r366", "r388", "r392", "r393", "r394", "r395", "r396", "r397", "r400", "r403", "r404", "r405", "r406", "r407", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r421", "r425", "r426", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r507" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r136", "r137", "r138", "r169", "r330", "r366", "r388", "r392", "r393", "r394", "r395", "r396", "r397", "r400", "r403", "r404", "r405", "r406", "r407", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r421", "r425", "r426", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r507" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r8", "r63", "r64", "r81", "r367", "r444", "r471" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock through underwritten offering, net of discounts and commissions and issuance costs of $6.6 million (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r8", "r81" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "RSU settlements (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r63", "r64", "r81", "r246" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Shares, Options exercised", "terseLabel": "Issuance of common stock upon exercise of stock options (in Shares)", "verboseLabel": "Performance-based stock options (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofstockoptionactivityTable", "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r8", "r63", "r64", "r81", "r376", "r444", "r471", "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock through underwritten offering, net of discounts and commissions and issuance costs of $6.6 million" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Reclassification of common stock warrants from liability to equity (Note 7)" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r8", "r63", "r64", "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of founders\u2019 restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r45", "r63", "r64", "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation expense" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r8", "r26", "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Stock Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r64", "r67", "r68", "r78", "r402", "r420", "r445", "r446", "r502", "r514", "r538", "r547", "r557", "r575" ], "calculation": { "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet", "http://Amplitudehealthcare.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r306", "r324" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r306", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r306", "r324" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails", "http://Amplitudehealthcare.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationImputedInterest": { "auth_ref": [ "r523" ], "calculation": { "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable": { "order": 2.0, "parentTag": "jspr_OperatingLeaseLiabilites", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "If disclosed, the amount of imputed interest necessary to reduce an unconditional purchase obligation to present value on an unrecorded unconditional purchase obligation.", "label": "Unrecorded Unconditional Purchase Obligation, Imputed Interest", "negatedLabel": "Less imputed interest" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationImputedInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofoperatingleaseliabilitiesshowingtheaggregateleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r36", "r37", "r38", "r99", "r100", "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageBasicSharesOutstandingProForma": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.", "label": "Weighted Average Basic Shares Outstanding, Pro Forma", "terseLabel": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageBasicSharesOutstandingProForma", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Outstanding and issued common stock options" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofdilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r152", "r163" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted", "verboseLabel": "Weighted average shares used to compute diluted net loss per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement_Parentheticals", "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation", "negatedLabel": "Less: Shares subject to earnout" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r151", "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in Shares)", "verboseLabel": "Weighted average shares used to compute basic net loss per share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ConsolidatedIncomeStatement", "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "negatedLabel": "Less: Weighted-average unvested restricted shares" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://Amplitudehealthcare.com/role/ScheduleofbasicanddilutednetlosspershareattributabletocommonstockholdersTable" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "a", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r516": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r517": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r518": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r519": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r521": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-5", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "805", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479835/944-805-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480463/815-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org//815/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479808/944-20-55-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" }